The proteoglycan versican is implicated in growth and metastases of several cancers. Here we investigated a potential contribution of stromal versican to tumor growth and angiogenesis. We initially determined versican expression by several cancer cell lines. Among these, MDA-MB231 and B16F10 had none to minimal expression in contrast to Lewis lung carcinoma (LLC). Notably, tumors arising from these cell lines had higher versican levels than the cell lines themselves suggesting a contribution from the host-derived tumor stroma. In LLC-derived tumors, both the tumor and stroma expressed versican at high levels. Thus, tumor stroma can make a significant contribution to tumor versican content. Versican localized preferentially to the vicinity of tumor vasculature and macrophages in the tumor. However, an ADAMTS protease-generated versican fragment uniquely localized to vascular endothelium. To specifically determine the impact of host/stroma-derived versican we therefore compared growth of tumors from B16F10 cells, which produced littleversican, in Vcan hdf/+ mice and wild-type littermates. Tumors in Vcan hdf/+ mice had reduced growth with a lower capillary density and accumulation of capillaries at the tumor periphery. These findings illustrate the variability of tumor cell line expression of versican, and demonstrate that versican is consistently contributed by the stromal tissue, where it contributes to tumor angiogenesis.
cleave versican at a specific site in the GAGβ region and ADAMTS4 has been shown to cleave an additional, poorly characterized site in the GAGα domain ( Supplementary Fig. S1C ) 9 . Versican turnover by ADAMTS proteases is well-characterized during embryogenesis and accompanies discrete morphogenetic events [30] [31] [32] . ADAMTS proteolysis of the V1 isoform generates an N-terminal G1 domain-containing fragment named versikine, which was implicated in regulation of apoptosis during limb development and myeloma growth 33 . Previous studies suggested that versican cleavage by ADAMTS proteases also occurs during vascular remodeling [34] [35] [36] [37] , in human uterine leiomyoma 38 and in human myeloma 33 . However, the spatial and causal relationship between versican, versican cleavage and tumor angiogenesis remains incompletely understood 39, 40 . Here, we investigated the contribution of stromal production of versican and of versican cleavage to tumor angiogenesis.
Results
Tumor cell lines show varying levels of versican expression. Versican mRNA and protein levels have not been systematically compared in experimentally used cancer cell lines and tumors arising from them. We first examined the expression of splice variants V0, V1, and V2 ( Supplementary Fig. S2 ) in commonly used cancer cell lines. By reverse transcription PCR (RT-PCR) and quantitative RT-PCR (qPCR), minimal versican V0, V1 and V2 mRNA expression was seen in MDA-MB231-cells relative to human skin fibroblasts ( Supplementary Fig. S2A,B) . Similarly, B16F10-cells did not express versican, whereas LLC cells showed high levels of Vcan V0 and V1 mRNA comparable to the aorta ( Supplementary Fig. S2C,D) . Western blotting confirmed a lack of versican GAGβ, representing isoforms V0/V1 in MDA-MB231-and B16F10-cells compared to LLC cells and mouse embryo lysate as a positive control (Fig. 1A) . Similarly, RT-PCR and qPCR for other cancer cell lines, MS-1, 4T-1, and SVR showed very low expression, while TRAMP-C1, TRAMP-C2 and FCB cell lines showed high levels of versican, comparable to mouse skin fibroblasts and mouse embryonic fibroblasts which are known for robust versican expression (data not shown). Thus, various cancer cell lines differ widely in their versican expression levels.
The tumor microenvironment contributes versican production. We next examined the contribution of stroma-derived versican in the tumor microenvironment. Based on the above finding of negligible versican production by B16F10-and MDA-MB231 cells, we selected them for subsequent analysis. We compared versican mRNA expression and content in the B16F10 and MDA-MB231 cells versus the respective tumors obtained by their injection into mice. Vcan V0/V1 mRNA was significantly higher in the B16F10 tumors than in cultured B16F10 cells (Fig. 1B) . VCAN V1 mRNA in MDA-MB231 cells and tumors were comparable (Fig. 1B) . In B16F10 tumors, both the host-and tumor derived versican would be of mouse origin and q-PCR detected the cumulative levels of mouse Vcan mRNA in tumor and host. In MDA-MB231 cells, q-PCR specifically detected human mRNA. Furthermore, even in tumors arising from LLC cells, which express versican robustly, we observed increased Vcan mRNA levels, suggestive of a contribution of tumor microenvironment (i.e., stroma) (Fig. 1B) .
Because we did not specifically assess host contribution in MDA-MB231 tumors by q-PCR, we selected to perform in situ hybridization using species-specific probes (see below). In contrast to Western blots of the cell lines (Fig. 1A) , the tumor Western blots showed abundant versican, although mostly in a variety of cleaved forms (Fig. 1C) . It should be noted that versican GAGβ antibody detected both mouse and human versican. These results suggested that the tumor microenvironment itself may contribute versican production or could potentially induce de-novo versican expression in tumor cells that do not express versican in culture. They also indicated extensive proteolysis of versican in the tumor microenvironment. Immunostaining for versican GAGβ showed specific staining at the periphery of B16F10-, LLC-and MDA-MB231-tumors, with the LLC tumors showing also strong staining in the tumor center (Fig. 1D) . The specificity of the versican GAGβ antibody was validated by staining embryonic mouse limbs 34 ( Supplementary Fig. S3A ). In situ hybridization with mouse probes demonstrated that Vcan exon 7 and exon 8, encoding versican GAGα and GAGβ domains, were both expressed at the tumor periphery in B16F10-derived tumors (Fig. 1E) . In contrast, the tumors derived from LLC-cells showed strong expression throughout the tumor (Fig. 1E ). These findings are consistent with immunostaining ( Fig. 1D ) and suggest that in B16F10-derived tumors, versican arises from stromal cells invading from the periphery of the tumor. In LLC-derived tumors, versican was produced from both tumor and stromal cells. We next sought to determine the origin of versican in the MDA-MB231 tumors, which contain both human tumor cells and stromal cells of mouse origin. We performed in situ hybridization using probes designed against the human VCAN exon 7 or mouse Vcan exon 7 and 8. Vcan (mouse) probes specific for exon 7 and exon 8 detected positive signals in E16.5 mouse embryo sections ( Supplementary Fig. S4A -C) but not human umbilical cord ( Supplementary  Fig. S4F ). VCAN (human) exon 7 and exon 8-specific probes detected positive signals in human umbilical cord but not in mouse embryos ( Supplementary Fig. S4D-F) , demonstrating stringent species-specificity. With these species-specific probes, we observed positive signal for Vcan exon 7 and exon 8 in the MDA-MB231 xenograft tumors. The signal was strongest in the periphery of the tumor, especially over the bordering host/stromal tissue (Fig. 1F) . The majority of the tumor section, including large areas of tumor cells were negative. Together with the specificity of the mouse probe, this suggests that versican present in MDA-MB231 tumors originates from host-derived stromal cells. The precise stromal cell phenotype expressing the mRNA cannot be readily ascertained owing to the challenges of combining immunostaining with in situ hybridization on the same section. The VCAN exon 7 probe (human), gave no signal in the MDA-MB231 xenograft tumors (Fig. 1F) . Thus, these observations clearly indicate that tumor microenvironment consistently contributes versican production to the tumors arising from these different cell lines.
Host-derived versican is located in vasculature and in the vicinity of tumor macrophages. We co-stained for versican GAGβ and two endothelial markers, CD105, and CD31. This demonstrated that versican primarily localized to the vicinity of the vasculature in the MDA-MB231 tumors. However, the endothelial cells themselves, which were stained with CD105, and CD31, did not co-stain for versican ( Fig. 2A) studies have demonstrated that macrophages are essential for tumor angiogenesis 41, 42 , we examined the localization of macrophages (F4/80 + cells) in relation to versican. Versican GAGβ staining showed co-localization with macrophages in the vicinity of the vasculature. Our results suggested that macrophages which infiltrated to the tumor tissues may produce the stromal-derived versican or may bind to versican-rich ECM (Fig. 2) . Because versican aggregates with HA in various tissues, we combined biotinylated HA-binding protein (HABP) and anti-versican GAGβ staining which revealed their co-localization in the MDA-MB231 tumor stroma (Fig. 2) . The specificity of the HA association was demonstrated by staining of sections with or without prior hyaluronidase Fig. S5 ). A versican-HA complex is therefore a component of the tumor stroma. Furthermore, in association with macrophages, versican-HA complex was specifically localized to the vasculature which permeates solid tumors.
Cleaved versican is observed in the tumor vasculature. Cleavage of versican has been observed in vascular inflammation and pathological angiogenesis 31, 43 . We analyzed ADAMTS-cleaved versican using anti-DPEAAE, which specifically detects the neoepitope resulting from proteolysis of versican at the Glu 441 -Ala 442 site (V1 sequence enumeration) 44 . Western blotting detected both the expected 220 kDa and 70 kDa band in the MDA-MB231 tumors indicating cleavage of V0 and V1 respectively by ADAMTS proteases 45, 46 . An additional 53 kDa anti-DPEAAE reactive band that presumably arises by cleavage within the G1 domain was observed. These findings indicated ADAMTS proteolytic activity in the tumor (Fig. 3A) . Immunostaining with anti-DPEAAE, which stained E13.5 mouse embryo interdigital tissue as a positive control ( Supplementary Fig. S3B ) showed staining at the periphery of MDA-MB231 tumors as well as in vascular strands permeating the tumors (Fig. 3B ). Overlapping staining with anti-GAGβ was thus seen, but in contrast to versican GAGβ, anti-DPEAAE signal was specifically localized to CD31 and CD105 positive cells within MDA-MB231 tumors (Fig. 3B,C) .
Furthermore, anti-DPEAAE signal in endothelial cells was distinct from HABP staining (Fig. 3B ) although anti-DPEAAE showed distinct overlap with macrophages labeled by F4/80 (Fig. 3B) as we observed in GAGβ staining. Similar versican distribution, that is, positive signals closely associated with the vasculature, was observed in B16F10-and LLC-tumors and cleaved versican was similarly specifically associated with the endothelial cells (Fig. 4A,B) . These results indicated that cleaved versican relocated to endothelial cells after cleavage of versican in the perivascular stroma. Genetic reduction of versican attenuates tumor angiogenesis and reduces tumor growth. To determine the influence of host versican on tumor angiogenesis, we compared tumor growth and tumor angiogenesis in B16F10 tumors formed in Vcan hdf/+ mice (haploinsufficient for versican), and wild-type littermates. B16F10 cells were chosen since our analysis indicated that these cells expressed little versican even when they formed tumors. Thus we could determine the host contribution in isolation. By immunoblotting, we first confirmed versican GAGβ reduction in Vcan hdf/+ mouse tumor as compared with that of wild-type (Fig. 5A ). We observed a significant reduction of tumor volume in the Vcan hdf/+ mice at 10 days and 13 days post-injection compared to wild-type mice (Fig. 5B,C) . In addition, B16F10 tumors in Vcan hdf/+ mice had fewer capillaries than wild-type (Fig. 5D,E) . Interestingly, we observed a high capillary density at the periphery of tumors in Vcan hdf/+ mice, with few capillaries penetrating into the center, suggesting impaired vascular invasion into the tumor interior (Fig. 5F ). Thus, these results suggest that host-derived versican, or cleaved versican facilitated tumor growth and angiogenesis.
Discussion
These studies provide a number of new insights. We show that tumor cell lines, which have not been previously systematically studied in this manner, differ considerably in their versican expression levels. Previous studies have mostly focused on the versican expressed by tumor cells or not attempted to distinguish between stromal and cancer cell versican expression [47] [48] [49] . Our findings suggest that, in addition to the tumor-derived versican, the stroma-derived versican is extremely relevant in specific cancer models (Fig. 6) . We demonstrated that in all the tumors investigated, versican of host (i.e., stromal origin) was distributed in the tumor periphery and associated with the tumor vasculature and its connective tissue that invades the tumor. In addition, the distribution of ADAMTS-protease cleaved versican showed a relocation of the N-terminal G1-domain-containing versican fragment, also called versikine, as compared with intact versican. A previous report showed that in limb bud development, cleaved versican had a different distribution from that of intact versican in association with apoptosis in interdigital tissue 34 . The present results were in line with the previous results, and suggests an independent role of versikine, a proteolytically generated versican fragment (Fig. 6) . Finally, the studies show that tumorigenesis and angiogenesis were both impaired in Vcan haploinsufficient mice. Another significance of this work relates to the frequent association of high tumor versican levels with higher cancer grade and adverse outcome 50 . Our studies suggest that where tumor-derived versican is present in addition to stromal versican there will be higher overall versican levels. Our studies also suggest that this is likely to contribute to accelerated vascular invasion and/or angiogenesis, which would enhance tumor growth. The present findings are not in agreement with a prior study in which tumorigenesis was undertaken using a versican-negative fibrosarcoma cell line and adenovirus Cre-induced stromal Vcan inactivation 51 . In contrast to the present analysis, the authors of that study concluded that stromal versican was inhibitory to angiogenesis and tumor growth. The contrasting findings could reflect different tumor and mouse models used in our respective approaches.
ADAMTS proteases have a major role in versican turnover during morphogenesis 9 . Our results suggest that ADAMTS proteases, such as ADAMTS-1, -4, -5 and -9 arising from endothelial cells and known to cleave versican 37 may act in the perivascular region, and the cleaved versican may be relocated to endothelial cells through as yet unknown mechanisms. Overexpression, silencing or mutation of ADAMTS proteases has been reported in a variety of cancers 52 , among them the versican-degrading metalloproteases ADAMTS-1, -4, -5, -9 and -20 32,53-55 . These proteases may well have other roles in cancer through cleavage of additional substrates and thus the role of ADAMTS proteases in cancer progression needs to be further investigated. In addition, relocation of versikine to endothelial cells and reduced angiogenesis upon Vcan haploinsufficiency hints at a biological effect of versikine on angiogenesis requiring further investigation. It is interesting that many extracellular matrix protein fragments (termed matrikine or matricryptins) arising from proteolytic cleavage have been implicated in angiogenesis and other processes [56] [57] [58] . Because several ADAMTS proteases can degrade versican, not only one particular ADAMTS, but ADAMTS proteases working in combination and with other protease classes may cooperate in complex patterns of versican fragmentation that need to be investigated. Indeed, each of the tumor Western blots showed extensive versican fragmentation. Because versican haploinsufficiency impaired proper tumor vessel invasion, it will be important to discriminate between the roles of intact and cleaved versican. Future studies using mice with cleavage-resistant versican or treatment with recombinant versikine could resolve these questions. Taken together, our findings suggest that versican is an intriguing target to consider in combating tumor growth and angiogenesis. 
Materials and Methods
Mouse strains and cell lines. All animal experiments were performed in accordance with relevant guidelines and regulations and approved by institutional committees at Okayama University (#OKU-2016 500, #OKU-2017 174 and #OKU-2017 175) and the Cleveland Clinic (Protocol 2013-1137). C57BL/6 wild-type mice and BALB/c nude mice were purchased from Charles River Japan, Yokohama, Japan. Vcan hdf/+ mice 59 were obtained under a material transfer agreement with Roche Pharmaceuticals and were maintained by outcrossing to C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME, USA). MDA-MB231 human breast tumor cell line and the B16F10 melanoma cell line were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and mouse LLC was purchased from European Collection of Authenticated Cell Cultures (ECACC, Public Health England, UK) 60 . Normal human skin fibroblasts (HSF) were purchased from Lonza Japan (Tokyo, Japan) and cultured with fibroblast basal growth medium-2 BulletKit and cells prior to passage 10 were used for analysis as previously described 61 . MDA-MB231, B16F10 and LLC cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were cultured at 37 °C under 20% O 2 and 5% CO 2 condition in a humidified incubator. RNA extraction, RT-PCR and qPCR. To determine gene expression, 2 × 10 5 MDA-MB231, B16F10, LLC cells and HSF were seeded in 12 well plates and cultured for 24-48 hours. Total RNA was extracted using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA), as previously described 62, 63 . Briefly, B16F10 and LLC tumors, mouse aorta and brain were homogenized with TRIzol for total RNA extraction according to the manufacturer's protocol. The RNA was kept at -80 °C until used for the experiments. The RNA concentration was measured using NanoDrop (Thermo Fisher Scientific) and 2 μg/20 μL of RNA was used for reverse transcription (ReverTra Ace, Thermo Fisher Scientific) at 30 °C for 10 minutes, 42 °C for 60 minutes and at 85 °C for 10 minutes as previously described 64, 65 . Human brain cDNA was obtained by reverse transcription of human brain total RNA (Thermo Fisher Scientific). The cDNA was diluted five-fold prior to PCR. RT-PCR was performed using rTaq DNA polymerase (Takara Bio Inc., Kusatsu, Japan) with specific primers 66 . Primers used for RT-PCR were shown in Supplementary Table S1 . Amplified products were electrophoresed on 2% agarose gels. For qPCR, 1 μL cDNA was mixed with TaqMan Fast Advanced Master Mix and specific primer pairs for VCAN V0 and V1 isoforms and Vcan V0 and V1 mRNAs (Thermo Fisher Scientific) according to the manufacturer's protocol. Gene expression was normalized using RPLP2 (for human) and Gapdh (for mouse) primers respectively. TaqMan primers used for qPCR were; VCAN V0, Hs01007944_m1; VCAN V1, Hs01007937_m1; RPLP2, Hs01115128_gH; Vcan V0/V1, Mm00490174_m1; mouse Gapdh, Mm99999915_g1. Gene expression was analyzed by ∆∆Ct method as previously described [67] [68] [69] . All experiments were repeated at least three times independently.
Tumor-bearing mouse models. 1 .0 × 10 6 MDA-MB231 cells suspended in 100 μL of DMEM were injected subcutaneously in BALB/c nude mice (7-10 week old female) as previously described 70, 71 . Similarly, B16F10 and LLC cells were implanted in the skin of C57BL/6 mice (including Vcan hdf/+ and wild-type littermates; 7-10 week old female). Tumor growth was measured with a Vernier caliper every two or three days. Tumor volume was determined by the formula (volume = length × width 2 × 0.52). Mice were euthanized when or before the tumor size reached 500-1000 mm 3 and the tumor tissues were dissected for following experiments.
Immunohistochemistry. Tumors 488 (S11223, Thermo Fisher Scientific, 1:500). Nuclei were stained with Hoechst dye (Sigma-Aldrich) before coverslip mounting for immunofluorescence and confocal laser scanning microscopy (model LSM780, Zeiss, Oberkochen, Germany) at the Central Research Laboratory, Okayama University Medical School. To detect HA, tissues were treated with HABP (2 μg/mL concentrations, Hokudo, Sapporo, Japan) overnight at 4 °C then reacted with Alexa Fluor 488 streptavidin conjugate. For the HA digestion, tissues were pretreated with 0.1 M sodium acetate pH 6.0 buffer for 15 minutes at 37 °C and then treated with 10 Turbidity Reducing Unit (TRU) /mL of Streptomyces hyalurolyticus hyaluronidase (Amano Enzyme, Nagoya, Japan) with the buffer for 2 hours at 60 °C prior to the HABP reaction. All experiments were repeated at least three times, independently.
RNA in situ hybridization. For in situ hybridization, we used the RNAScope method (Advanced Cell Diagnostics, Newark, CA, USA) with specific probes targeting VCAN exon 7 (452231 Red) or exon 8 (452241 Red) (encoding the GAGα and GAGβ domains respectively) or Vcan exon 7 (428311 Red) or exon 8 (428321 Red). As a control for versican RNA expression, human umbilical cord was obtained under approval from the Cleveland Clinic Institutional Review Board with an exemption (exemption 4) for the use of discarded human tissue without patient identifiers. 7 µm sections were cut immediately prior to in situ hybridization, de-paraffinized and hybridized to the probes using the RNAScope 2.0 HD Red detection kit and HybEZ TM oven (Advanced Cell Diagnostics) according to the manufacturer's instructions. Sections were stained with hematoxylin and then treated with ammonium hydroxide to acquire blue counter staining as previously described 72 .
Western blotting. 5 × 10 5 MDA-MB231-, B16F10-and LLC-cells were independently seeded on 6-well plates and cultured for 24 hours. Culture medium was replaced with FBS-free medium and then cultured for a further 24 hours. Conditioned media were filtered with 0.22 μm pore filter and centrifuged and supernatant was stored at −80 °C. Cells were lysed with CelLytic M Mammalian Cell Lysis/Extraction Reagent (Sigma-Aldrich) and centrifuged. The MDA-MB231 xenograft tumors were homogenized with lysis buffer (T-PER Tissue Protein Extraction Reagent, Thermo Fisher Scientific) and centrifuged as previously described. Proteinase inhibitor (Roche, Basel, Switzerland) was added to the lysis buffer to protect protein degradation. Protein concentration was measured using Pierce BCA Protein Assay kit (Thermo Fisher Scientific), according to the manufacturer's instruction. For the detection of versican GAGβ, chondroitinase digestion was performed as described above. Protein extracted from MDA-MB231 tumor (30 μg), E13.5 mouse embryo (15 μg) and cell lysates (15 μg) was used for Western blot analysis, as described previously 73, 74 . The primary antibodies were anti-versican GAGβ (as described above); anti-neoepitope DPEAAE (as described above); anti-β-actin (A5441, Sigma-Aldrich, 1:5000); and secondary antibodies for anti-rabbit IgG HRP conjugated (55676, MP Biomedicals, Santa Ana, CA, USA, 1:2000); and anti-mouse IgG HRP conjugated (sc-2005, Santa Cruz, Dallas, Texas, USA, 1:2000) were used and developed by using Amersham ECL Prime (GE Healthcare, Buckinghamshire, England, UK). All experiments were repeated at least three times, independently.
Statistical analysis.
All values are given as the mean ± S.D. Between-group variations were assessed using the two-tailed unpaired t-test. For multiple comparisons, analysis of variance was performed, with post-hoc analysis with the Bonferroni test. P values < 0.05 were considered significant.
